Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and ASCT in Relapsed DLBCL
NCT00052923Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Mar 2003
- Primary completion
- Jun 2006
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Rituximab Maintenance with Observation (2 arms). Primary endpoint: Progression-Free Survival. Started Mar 2003; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00052923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052923.